Clinical Trials (PDQ®)
|Phase II||Treatment||Completed||18 and over||Other||CRAD0012467|
Swedish Cancer Institute 05128, NCT00337545
Single center open-label study of an oral agent (RAD001) in subjects with metastatic colorectal cancer refractory to at least 2 standard chemo/biologic regimens.
Further Study Information
Study is completed and closed.
- Metastatic colorectal cancer refractory to at least 2 chemo/biologic regimens
- Measurable disease
- ECOG 0-2
- CNS disease
- Chemotherapy or radiotherapy < 4 weeks prior
- Active bleeding diathesis
Trial Lead Organizations/Sponsors
Swedish Cancer Institute at Swedish Medical Center - First Hill CampusNovartis Pharmaceuticals Corporation
|Philip J. Gold||Principal Investigator|
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00337545
ClinicalTrials.gov processed this data on October 20, 2014
Back to Top